class="wp-theme-Newspaper supp-body td-standard-pack global-block-template-1 tdc-header-template tdc-footer-template td-animation-stack-type0 td-full-layout"
FDA 1999 FINAL RULE: colloidal silver products are NOT safe or effective for any condition claimed. ARGYRIA: Irreversible permanent blue-grey/slate discolouration of skin, mucous membranes, and organs due to silver accumulation — no treatment exists. Neurological toxicity. Antibiotic interference (reduces absorption of antibiotics). Drug interactions: tetracyclines, quinolone antibiotics, penicillamine, thyroxine. Banned/restricted as supplement in USA, EU, Australia, Canada.
Colloidal suspension of silver nanoparticles marketed for antimicrobial, immune-boosting, and anti-aging effects. FDA ruled in 1999 that colloidal silver is NOT generally recognised as safe (GRAS) for any condition. EFSA and TGA concur. Causes argyria (irreversible blue-grey skin discolouration). No legitimate supplement use.
Acts on cellular signalling pathways relevant to the documented clinical indications. Contains bioactive compounds with enzyme-modulating, receptor-binding, or antioxidant properties studied in peer-reviewed literature.
| Population | Safety rating | Max safe dose |
|---|---|---|
| General | Likely unsafe | — |
| Pregnancy | Likely unsafe | — |
| Elderly | Likely unsafe | — |
No peer-reviewed clinical trial data found for this ingredient.
Data by supplement.ge — Public Health Institute of Georgia (PHIG)